Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 673

1.

An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome.

Sawyer JR, Tian E, Walker BA, Wardell C, Lukacs JL, Sammartino G, Bailey C, Schinke CD, Thanendrarajan S, Davies FE, Morgan GJ, Barlogie B, Zangari M, van Rhee F.

Blood Cancer J. 2019 Aug 9;9(8):62. doi: 10.1038/s41408-019-0226-4.

2.

Bone marrow morphologic features, MyPRS, and gene mutation correlations in plasma cell myeloma.

Hao Y, Khaykin D, Machado L, van den Akker T, Houldsworth J, Barlogie B, Hussein S, El Jamal SM, Petersen B, Teruya-Feldstein J.

Mod Pathol. 2019 Aug 2. doi: 10.1038/s41379-019-0333-6. [Epub ahead of print]

PMID:
31375765
3.

Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis?

Rasche L, Kumar M, Gershner G, Samant R, Van Hemert R, Heidemeier A, Lapa C, Bley T, Buck A, McDonald J, Hillengass J, Epstein J, Thanendrarajan S, Schinke C, van Rhee F, Zangari M, Barlogie B, Davies FE, Morgan GJ, Weinhold N.

Theranostics. 2019 Jul 9;9(16):4756-4763. doi: 10.7150/thno.33289. eCollection 2019.

4.

PET-Computed Tomography in Myeloma: Current Overview and Future Directions.

Madduri D, Barlogie B.

PET Clin. 2019 Jul;14(3):411-418. doi: 10.1016/j.cpet.2019.03.010. Review.

PMID:
31084780
5.

Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics Approach.

Laganà A, Beno I, Melnekoff D, Leshchenko V, Madduri D, Ramdas D, Sanchez L, Niglio S, Perumal D, Kidd BA, Miotto R, Shaknovich R, Chari A, Cho HJ, Barlogie B, Jagannath S, Dudley JT, Parekh S.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00019. Epub 2018 Aug 8.

6.

Daratumumab-induced transient myopic shift.

Mavrommatis MA, Jung H, Chari A, Barlogie B, Chelnis JG.

Am J Ophthalmol Case Rep. 2018 Dec 18;13:116-118. doi: 10.1016/j.ajoc.2018.12.017. eCollection 2019 Mar.

7.

Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma.

Rasche L, Alapat D, Kumar M, Gershner G, McDonald J, Wardell CP, Samant R, Van Hemert R, Epstein J, Williams AF, Thanendrarajan S, Schinke C, Bauer M, Ashby C, Tytarenko RG, van Rhee F, Walker BA, Zangari M, Barlogie B, Davies FE, Morgan GJ, Weinhold N.

Leukemia. 2019 Jul;33(7):1713-1722. doi: 10.1038/s41375-018-0329-0. Epub 2018 Dec 20.

8.

Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project.

Usmani SZ, Hoering A, Cavo M, Miguel JS, Goldschimdt H, Hajek R, Turesson I, Lahuerta JJ, Attal M, Barlogie B, Lee JH, Kumar S, Lenhoff S, Morgan G, Rajkumar SV, Durie BGM, Moreau P.

Blood Cancer J. 2018 Nov 23;8(12):123. doi: 10.1038/s41408-018-0155-7.

9.

Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes.

Mehdi SJ, Johnson SK, Epstein J, Zangari M, Qu P, Hoering A, van Rhee F, Schinke C, Thanendrarajan S, Barlogie B, Davies FE, Morgan GJ, Yaccoby S.

Br J Haematol. 2019 Feb;184(4):578-593. doi: 10.1111/bjh.15669. Epub 2018 Nov 8.

PMID:
30408155
10.

Walking on myeloma.

Barlogie B, Richter J.

Blood. 2018 Oct 18;132(16):1724. doi: 10.1182/blood-2018-07-861096. No abstract available.

PMID:
30337321
11.

Gene Expression Profiling Reveals Aberrant T-cell Marker Expression on Tumor Cells of Waldenström's Macroglobulinemia.

Hao M, Barlogie B, Tricot G, Liu L, Qiu L, Shaughnessy JD Jr, Zhan F.

Clin Cancer Res. 2019 Jan 1;25(1):201-209. doi: 10.1158/1078-0432.CCR-18-1435. Epub 2018 Oct 2.

12.

Clinical Presentation and Gene Expression Profiling of Immunoglobulin M Multiple Myeloma Compared With Other Myeloma Subtypes and Waldenström Macroglobulinemia.

Atrash S, Zhang Q, Papanikolaou X, Stein C, Abdallah AO, Barlogie B.

J Glob Oncol. 2018 Sep;4:1-8. doi: 10.1200/JGO.2016.008003. Epub 2017 May 9.

13.

Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials.

Ailawadhi S, Jacobus S, Sexton R, Stewart AK, Dispenzieri A, Hussein MA, Zonder JA, Crowley J, Hoering A, Barlogie B, Orlowski RZ, Rajkumar SV.

Blood Cancer J. 2018 Jul 6;8(7):67. doi: 10.1038/s41408-018-0102-7.

14.

Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling.

Wu V, Moshier E, Leng S, Barlogie B, Cho HJ, Jagannath S, Madduri D, Mazumdar M, Parekh S, Chari A.

Blood Adv. 2018 Jun 26;2(12):1470-1479. doi: 10.1182/bloodadvances.2018016998. Erratum in: Blood Adv. 2018 Sep 11;2(17):2186.

15.

Imipridone ONC201: combination therapy in hematologic malignancies.

Chari A, Barlogie B.

Cell Cycle. 2018;17(16):1947-1948. doi: 10.1080/15384101.2018.1490861. Epub 2018 Sep 11. No abstract available.

16.

The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma.

Rasche L, Angtuaco EJ, Alpe TL, Gershner GH, McDonald JE, Samant RS, Kumar M, Van Hemert R, Epstein J, Deshpande S, Tytarenko R, Yaccoby S, Hillengass J, Thanendrarajan S, Schinke C, van Rhee F, Zangari M, Walker BA, Barlogie B, Morgan GJ, Davies FE, Weinhold N.

Blood. 2018 Jul 5;132(1):59-66. doi: 10.1182/blood-2018-04-842880. Epub 2018 May 21.

17.

Antigen-mediated regulation in monoclonal gammopathies and myeloma.

Nair S, Sng J, Boddupalli CS, Seckinger A, Chesi M, Fulciniti M, Zhang L, Rauniyar N, Lopez M, Neparidze N, Parker T, Munshi NC, Sexton R, Barlogie B, Orlowski R, Bergsagel L, Hose D, Flavell RA, Mistry PK, Meffre E, Dhodapkar MV.

JCI Insight. 2018 Apr 19;3(8). pii: 98259. doi: 10.1172/jci.insight.98259. eCollection 2018 Apr 19.

18.

Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma.

Davies FE, Rosenthal A, Rasche L, Petty NM, McDonald JE, Ntambi JA, Steward DM, Panozzo SB, van Rhee F, Zangari M, Schinke CD, Thanendrarajan S, Walker B, Weinhold N, Barlogie B, Hoering A, Morgan GJ.

Haematologica. 2018 Jun;103(6):1047-1053. doi: 10.3324/haematol.2017.177139. Epub 2018 Mar 22.

19.

The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma.

Schinke C, Qu P, Mehdi SJ, Hoering A, Epstein J, Johnson SK, van Rhee F, Zangari M, Thanendrarajan S, Barlogie B, Davies FE, Yaccoby S, Morgan GJ.

Clin Cancer Res. 2018 Jun 15;24(12):2913-2919. doi: 10.1158/1078-0432.CCR-17-2627. Epub 2018 Mar 21.

20.

The effect of novel therapies in high-molecular-risk multiple myeloma.

Lancman G, Tremblay D, Barley K, Barlogie B, Cho HJ, Jagannath S, Madduri D, Moshier E, Parekh S, Chari A.

Clin Adv Hematol Oncol. 2017 Nov;15(11):870-879. Review.

Supplemental Content

Loading ...
Support Center